Last reviewed · How we verify

Opioid-free Anesthesia-Analgesia Strategy

University of Crete · FDA-approved active Small molecule

Opioid-free Anesthesia-Analgesia Strategy is a Small molecule drug developed by University of Crete. It is currently FDA-approved for Perioperative anesthesia and analgesia for surgical procedures. Also known as: Opioid-Free Anesthesia, OFA-A.

A multimodal anesthesia-analgesia strategy that avoids opioid medications by combining regional anesthesia, local anesthetics, and non-opioid analgesics.

A multimodal anesthesia-analgesia strategy that avoids opioid medications by combining regional anesthesia, local anesthetics, and non-opioid analgesics to provide perioperative pain control. Used for Perioperative anesthesia and analgesia in surgical patients.

At a glance

Generic nameOpioid-free Anesthesia-Analgesia Strategy
Also known asOpioid-Free Anesthesia, OFA-A
SponsorUniversity of Crete
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

This approach uses a combination of techniques including neuraxial blockade, peripheral nerve blocks, local infiltration anesthesia, and non-opioid systemic medications (such as NSAIDs, acetaminophen, ketamine, and dexmedetomidine) to achieve anesthesia and analgesia without relying on opioid drugs. The strategy aims to reduce opioid-related adverse effects including respiratory depression, addiction potential, and postoperative nausea while maintaining effective pain control and anesthetic depth.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Opioid-free Anesthesia-Analgesia Strategy

What is Opioid-free Anesthesia-Analgesia Strategy?

Opioid-free Anesthesia-Analgesia Strategy is a Small molecule drug developed by University of Crete, indicated for Perioperative anesthesia and analgesia for surgical procedures.

How does Opioid-free Anesthesia-Analgesia Strategy work?

A multimodal anesthesia-analgesia strategy that avoids opioid medications by combining regional anesthesia, local anesthetics, and non-opioid analgesics.

What is Opioid-free Anesthesia-Analgesia Strategy used for?

Opioid-free Anesthesia-Analgesia Strategy is indicated for Perioperative anesthesia and analgesia for surgical procedures.

Who makes Opioid-free Anesthesia-Analgesia Strategy?

Opioid-free Anesthesia-Analgesia Strategy is developed and marketed by University of Crete (see full University of Crete pipeline at /company/university-of-crete).

Is Opioid-free Anesthesia-Analgesia Strategy also known as anything else?

Opioid-free Anesthesia-Analgesia Strategy is also known as Opioid-Free Anesthesia, OFA-A.

What development phase is Opioid-free Anesthesia-Analgesia Strategy in?

Opioid-free Anesthesia-Analgesia Strategy is FDA-approved (marketed).

What are the side effects of Opioid-free Anesthesia-Analgesia Strategy?

Common side effects of Opioid-free Anesthesia-Analgesia Strategy include Hypotension, Bradycardia, Local anesthetic toxicity, Nerve injury from regional blocks.

Related